Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front‐li...
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front‐line chemotherapy regimens
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Background
Front‐line platinum‐base chemotherapy for advanced thymoma and thymic carcinoma (TC) improves resectability and prolongs patients' overall survival (OS). In this study, we evaluated patients' outcomes given different front‐line regimens: cisplatin, doxorubicin, and cyclophosphamide (CAP); cisplatin and etoposide (EP); or cisplatin and...
Alternative Titles
Full title
Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front‐line chemotherapy regimens
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e574cac37ef049b4843c2bd862c774dd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e574cac37ef049b4843c2bd862c774dd
Other Identifiers
ISSN
2045-7634
E-ISSN
2045-7634
DOI
10.1002/cam4.4711
